Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zevra Therapeutics Inc ZVRA

Healthcare
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered... see more

Recent & Breaking News (NDAQ:ZVRA)

KemPharm Files IND for KP879 for the Treatment of Stimulant Use Disorder

GlobeNewswire December 22, 2020

KemPharm Participates in KP415 Late-Cycle Communication Meeting with FDA

GlobeNewswire December 2, 2020

REMINDER: KemPharm and Corium to Co-Host "KP415 Market Opportunity and Commercialization Strategy" Investor Event

GlobeNewswire November 30, 2020

KemPharm Provides Update on Development Pipeline

GlobeNewswire November 23, 2020

KemPharm and Corium to Co-Host "KP415 Market Opportunity and Commercialization Strategy" Investor Event

GlobeNewswire November 18, 2020

KemPharm Reports Third Quarter 2020 Financial Results

GlobeNewswire October 29, 2020

KemPharm Postpones Special Meeting of Stockholders, Announces Date for Q3 2020 Results Call

GlobeNewswire October 26, 2020

KemPharm's KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the AACAP 2020 Virtual Meeting

GlobeNewswire October 22, 2020

KemPharm and Corium Expand Relationship with New Consultation Services Agreement

GlobeNewswire October 5, 2020

KemPharm Files Preliminary Proxy for Special Meeting of Stockholders

GlobeNewswire September 25, 2020

KemPharm's Commercial Partner for APADAZ®, KVK-Tech, Enters into Collaboration Agreement with Sure Med Compliance Focused on Improving Prescribing Education and Compliance for Pain Therapies

GlobeNewswire September 10, 2020

KemPharm to Present at Upcoming September Investor Conferences

GlobeNewswire September 2, 2020

KemPharm Participates in KP415 Mid-Cycle Communication Meeting with FDA

GlobeNewswire August 14, 2020

KemPharm Reports Second Quarter 2020 Financial Results

GlobeNewswire August 12, 2020

KemPharm to Report Second Quarter 2020 Financial Results

GlobeNewswire August 4, 2020

KemPharm Announces Issuance of Two Additional U.S. Patents Governing KP415 and KP484

GlobeNewswire July 28, 2020

KemPharm Issues Letter to Shareholders

GlobeNewswire June 18, 2020

KemPharm Receives Day-74 Letter for KP415 NDA

GlobeNewswire May 19, 2020

KemPharm Reports First Quarter 2020 Financial Results

GlobeNewswire May 12, 2020

KemPharm to Report First Quarter 2020 Financial Results

GlobeNewswire May 6, 2020